Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 2005

View Archived Issues

MF-101: a safer alternative for hormonal therapy

In vivo studies confirm the anti-HSV activity of a cream formulation of resveratrol

Anti-HBV activity of ellagic acid

Vestipitant shows anxiolytic-like profile in rodent and primate behavioral models

DPI-221 shows potential as an agent for overactive bladder and urinary incontinence

Scientists describe advantages of using two antibodies in PAGRIT

Aripiprazole reported effective in preventing relapse of patients with bipolar disorder

Scientists find link between novel locus and left main coronary artery disease risk

Phase II study discontinued for vicriviroc in treatment-naive HIV patients

Cellegy completes enrollment in phase III HIV prevention study of Savvy

Approval of muraglitazar may require new trials

Enrollment begins in phase I Chemophase study

Biolex to create commercial line for Kringle's NK4 protein

Update on ongoing Avian flu research

Positive phase III results for GSK drug from Flamel collaboration

Dacogen under review in U.S. and Europe for MDS

Positive phase I findings for Fentanyl Taifun

Chromos Molecular Systems to acquire Targeted Molecules

Accelerated approval for Arranon

FDA extends Exubera review period

Erbitux sBLA accepted for filing, granted priority review

Cerepro MAA accepted for review

Schering-Plough seeks Japanese approval of Temodal

Escitalopram reported to improve kleptomania, PMDD and depression

MD-1100 demonstrates gastrointestinal activity in healthy volunteers

Novel antiinfective agents emerge from sanofi-aventis R&D

New therapeutic agents claimed for metabolic disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Sun Pharma to acquire Merck spinoff Organon for $11.75B
BioWorld
Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of...